The drug substance patent on Dasatinib was owned by Bristol-Myers-Squibb and had expired on 12 April 12, 2020. The current monthly therapy cost of innovator is approximately Rs 1.65 lakh, Shilpa Medicare said in a regulatory filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2S4g05R
via IFTTT
0 comments:
Post a Comment